-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were
Search Results
Robin M. Lally, Elizabeth Reed, and Roksana Zak
Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver
Center Educational Forum attendees illustrated a theme related to adjuvant therapy delay. Providers were surprised to learn that as many as 10% of patients were not recorded as receiving adjuvant endocrine therapy. Performance on this measure did not
Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.
1990 ; 66 : 56 – 61 . 7 Whittington R Bryer MP Haller DG . Adjuvant therapy of resected adenocarcinoma of the pancreas . Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137 – 1143 . 8 Abrams RA . Adjuvant therapy for pancreatic
Rosalyn A. Juergens and Julie R. Brahmer
. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer . Eastern Cooperative Oncology Group . N Engl J Med 2000 ; 343 : 1217 – 1222 . 20. Mineo TC Ambrogi V
Roy H. Decker and Lynn D. Wilson
the addition of adjuvant therapy . J Clin Oncol 2005 ; 23 : 7236 – 7237 . 13. Wilson LD Gruber SB . Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass
, adjuvant chemotherapy. 10 Population and institutional studies have shown that adjuvant therapy may confer a survival advantage in some patients with resected colon cancer (eg, those with stage III or high-risk stage II disease). 11 – 14 Furthermore
NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Featured Updates to the NCCN Guidelines
Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K. Narang, Christos Fountzilas, Brian M. Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, George Fisher, Jeffrey Hardacre, William G. Hawkins, Andrew H. Ko, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A. Wolff, Jennifer L. Burns, and Griselda Zuccarino-Catania
only approximately half of patients with potentially curative resections receive adjuvant therapy due to issues associated with postoperative complications, recovery, and performance status. 9 Median survival for patients with resected tumors under
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee
without records of adjuvant therapy were excluded. Patients were identified from a prospectively maintained breast cancer database at an NCI-designated Comprehensive Cancer Center. Clinicopathologic variables, including demographic information, pathology
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes
ICIs. Immunotherapy Clinical Trial Data IMpower010, a phase III randomized trial, assessed adjuvant therapy with atezolizumab versus best supportive care in 1,005 patients with completely resected stage IB–IIIA NSCLC (staging
Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette
higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100
